Back20/20 Biolabs Common Stock Overview

20/20 Biolabs Common Stock Other Current Liabilities

Latest other current liabilities for AIDX: $860K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$864663.00

Peer trimmed avg / median

Loading

20/20 Biolabs Common Stock Other Current Liabilities History

Loading

20/20 Biolabs Common Stock vs. peers: Other Current Liabilities Comparison

Loading

20/20 Biolabs Common Stock Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

20/20 Biolabs Common Stock (AIDX) FAQ

20/20 Biolabs Common Stock posts a other current liabilities of $860K as of June 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Other Current Liabilities is one piece of 20/20 Biolabs Common Stock's financial statement story. At $860K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AIDX's other current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; 20/20 Biolabs Common Stock's other metric pages and overview cover the third.